News | June 10, 2022
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
Based on a post hoc analysis, fewer required respiratory interventions
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Subscribe To Our Newsletter & Stay Updated
